Fortun J, Munoz P, Montejo M, Aguado J, Carratala J, Tarrago D, Martin-Davila P; Interscience Conference on Antimicrobial Agents and Chemotherapy.

Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 1999 Sep 26-29; 39: 574 (abstract no. 1644).

The Gesitra Group, Seimc, Spain

BACKGROUND: Invasive fungal infections are a major cause of morbidity and mortality in transplant patients. Lipid formulations of amphotericin B have been developed in order to decrease the toxicity of conventional amphotericin B. However, advantage in clinical efficacy has not been fully demonstrated. OBJECTIVE: To evaluate the clinical efficacy and safety profile associated with liposomal amphotericin B (AmBisome[TM]) or lipid complex amphotericin B (Abelcet[TM]) in transplant patients from five Spanish hospitals. Patients: 56 pts. were treated, 43 with AmBisome[TM]and 13 with Abelcet[TM]. The transplanted organs were: liver 34, heart 16, BMT 4 and kidney-pancreas 2. Elevation of renal and liver function tests were defined as 20% and a 100% increase, compared with basal values of creatinine and AST/ALT/bilirubin, respectively; anemia, as hemoglobin decrease of 2 gr/dL.RESULTS: [table: see text].CONCLUSIONS: Mortality of fungal invasive infections in transplant patients remains high despite using new lipid preparations of amphotericin B. In this non-comparative study we were unable to find significant differences in toxicity or efficacy between AmBisome[TM]and Abelcet[TM].

Publication Types:

• Meeting Abstracts

Keywords:

• Abelcet
• AmBisome
• Amphotericin B
• Chemistry, Pharmaceutical
• Drug Combinations
• Humans
• Kidney
• Kidney Diseases
• Multicenter Study
• Mycoses
• Phosphatidylcholines
• Phosphatidylglycerols
• Transplants
• transplantation

Other ID:

• GWAIDS0009288

UI: 102246786

From Meeting Abstracts